The Pentavalent Rotavirus Vaccine: Discovery to Licensure and Beyond
Open Access
- 15 December 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (12), 1618-1624
- https://doi.org/10.1086/522997
Abstract
Twenty-five years passed between the discovery of the parent strain (WC3) of the pentavalent human-bovine reassortant rotavirus vaccine (PRV) in 1981 and the licensure of PRV in 2006. This orally administered liquid vaccine, which is given as a 3-dose series, is indicated for the prevention of rotavirus gastroenteritis, caused by the G serotypes contained in the vaccine, in infants and children. PRV is recommended by the Advisory Committee on Immunization Practices and the American Academy of Pediatrics for administration to all infants in the United States. These recommendations are supported by the results of the phase III studies, which demonstrated that PRV is well tolerated and efficacious. PRV reduced rotavirus-related hospitalizations by 96% and was not associated with an increased incidence of serious adverse events, including intussusception. This report focuses on the safety and efficacy data from the late-phase studies of PRV and discusses plans for providing this vaccine to the developing world.Keywords
This publication has 22 references indexed in Scilit:
- Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus VaccineNew England Journal of Medicine, 2006
- Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccineReviews in Medical Virology, 2004
- Global Illness and Deaths Caused by Rotavirus Disease in ChildrenEmerging Infectious Diseases, 2003
- Intussusception among Infants Given an Oral Rotavirus VaccineNew England Journal of Medicine, 2001
- Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populationsThe Journal of Pediatrics, 1997
- Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritisThe Lancet, 1997
- Rotavirus Infection in Infants as Protection against Subsequent InfectionsNew England Journal of Medicine, 1996
- The Development Of Multivalent Bovine Rotavirus (Strain Wc3) ReassortantThe Journal of Infectious Diseases, 1996
- Rotaviruses: Immunological Determinants of Protection Against Infection and DiseasePublished by Elsevier BV ,1994
- Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young childrenThe Journal of Pediatrics, 1977